BiotechPark with Innovation- and Incubationscenter
Berlin-Buch, with its long tradition of excellent biomedical basic and clinical research as well as clinical expertise, is an ideal environment for life science companies. The campus atmosphere is conducive to scientific exchange, technology transfer and collaborative projects.
With an area of approximately 31,000 m², the BiotechPark Berlin-Buch is one of the largest biotech parks in Germany. Here entrepreneurs and companies find affordable, industry-specific laboratory and office space with state-of-the-art facilities. Start-ups can grow and thrive in the Innovation and Incubation Center, building areas on the Campus allow for future development. The managing company, Campus Berlin-Buch GmbH, supports the companies in all matters and provides comprehensive service.
Currently, approximately 63 companies are located on campus and employ around 800 people. Forty-seven of these companies are in the biotech sector, several others offer services for the life science industry. Since 1998 the number of employees of the biotech companies has more than doubled.
The business fields of the companies range from medical technology products, molecular biological diagnostics and treatments, preclinical pharmacological and pharmacogenomic tests, RNA technologies, the search for pharma-relevant target molecules, production and testing of drugs and the analysis and synthesis of biomolecules.
„Made in Buch“ stands for high quality and innovation in the life sciences. Selected products can be found here.
Eckert & Ziegler: Executive Board Proposes Dividend and Share Split
Eckert & Ziegler AG (ISIN DE0005659700, S-DAX), a specialist for isotope-based applications in medicine, science and industry achieved earnings per share of 4.29 EUR in the fiscal year 2019. At the Ge...more ...
Eckert & Ziegler receives CE approval for innovative irradiation applicators using 3D printing
Eckert & Ziegler BEBIG has received CE approval for the world's first applicators manufactured by 3D printing and designed for the treatment of gynecological tumors.more ...
Eckert & Ziegler Classified in California as Essential Business
The production sites in California of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX), in fiscal year 2019 responsible for more than one third of the groups revenue, will n...more ...